SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target
MUMBAI – December 3, 2021, Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: ...
Read moreDetails
